ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,505.00
-0.71%
US Tech 100
19,000.00
-0.94%
Dow Jones
40,287.53
-0.93%
Brent Oil
82.295
0.02%
Bitcoin
67,717.27
-0.65%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. NRX Pharmaceuticals Inc (NRXP)

  7. NRX Pharmaceuticals Inc (NRXP) News

NRXP

NRX Pharmaceuticals (NRXP)

NRX Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NRXP
DateTimeSourceHeadlineSymbolCompany
07/01/20248:07AMPR Newswire (US)NRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update LetterNASDAQ:NRXPNRX Pharmaceuticals Inc
06/28/20248:07AMPR Newswire (US)NRx Pharmaceuticals (NASDAQ:NRXP) to Proceed with Two New Drug Applications in 2024; NRX-101 has Been Returned to the Company for FilingNASDAQ:NRXPNRX Pharmaceuticals Inc
06/20/20248:30AMPR Newswire (US)NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024NASDAQ:NRXPNRX Pharmaceuticals Inc
06/18/20248:30AMPR Newswire (US)NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Neuroscience, Information Technology and Medical Technology Veteran to its Board of DirectorsNASDAQ:NRXPNRX Pharmaceuticals Inc
06/10/20248:30AMPR Newswire (US)NRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update LetterNASDAQ:NRXPNRX Pharmaceuticals Inc
05/28/20248:30AMPR Newswire (US)NRx Pharmaceuticals (Nasdaq:NRXP) Presents Landmark Trial of NRX-101 in Suicidal Bipolar Depression At the American Society of Clinical Psychopharmacology Annual Meeting: NRX-101 is the First Oral Antidepressant Demonstrated to Reduce Suicidality in BipolaNASDAQ:NRXPNRX Pharmaceuticals Inc
05/14/20244:01PMPR Newswire (US)NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:NRXPNRX Pharmaceuticals Inc
05/08/20248:30AMPR Newswire (US)NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Participate in the EF Hutton Annual Global Conference on May 15, 2024NASDAQ:NRXPNRX Pharmaceuticals Inc
05/07/20244:01PMPR Newswire (US)NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Report First Quarter 2024 Financial Results on May 14, 2024NASDAQ:NRXPNRX Pharmaceuticals Inc
05/06/20248:30AMPR Newswire (US)NRx Pharmaceuticals (Nasdaq:NRXP) Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar DepressionNASDAQ:NRXPNRX Pharmaceuticals Inc
04/30/20248:30AMPR Newswire (US)NRx Pharmaceuticals (Nasdaq:NRXP) Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar DepressionNASDAQ:NRXPNRX Pharmaceuticals Inc
04/18/20248:32AMPR Newswire (US)NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price RequirementNASDAQ:NRXPNRX Pharmaceuticals Inc
04/18/20248:30AMPR Newswire (US)NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common StockNASDAQ:NRXPNRX Pharmaceuticals Inc
04/17/20244:45PMPR Newswire (US)NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common StockNASDAQ:NRXPNRX Pharmaceuticals Inc
04/17/20248:30AMPR Newswire (US)NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infectionsNASDAQ:NRXPNRX Pharmaceuticals Inc
04/15/20248:30AMPR Newswire (US)NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)NASDAQ:NRXPNRX Pharmaceuticals Inc
04/08/20248:30AMPR Newswire (US)NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar DepressionNASDAQ:NRXPNRX Pharmaceuticals Inc
04/01/20248:28AMPR Newswire (US)NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:NRXPNRX Pharmaceuticals Inc
03/28/20248:03AMPR Newswire (US)NRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and Provides Year End HighlightsNASDAQ:NRXPNRX Pharmaceuticals Inc
03/28/20248:00AMPR Newswire (US)NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq ListingNASDAQ:NRXPNRX Pharmaceuticals Inc
03/26/20244:03PMPR Newswire (US)UPDATE: NRx Pharmaceuticals (NASDAQ: NRXP) to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024NASDAQ:NRXPNRX Pharmaceuticals Inc
03/25/20248:30AMPR Newswire (US)NRx Pharmaceutical's (NASDAQ:NRXP) Chairman Dr. Jonathan Javitt to Present at the Ketamine 2024 Conference in Oxford, UKNASDAQ:NRXPNRX Pharmaceuticals Inc
03/21/20244:02PMPR Newswire (US)NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 28, 2024NASDAQ:NRXPNRX Pharmaceuticals Inc
03/21/20241:57PMPR Newswire (US)NRx Pharmaceuticals Announces Results of the Vote Held During the Special Meeting of ShareholdersNASDAQ:NRXPNRX Pharmaceuticals Inc
03/12/20247:49AMPR Newswire (US)NRx Pharmaceuticals (NASDAQ:NRXP) Initiates Strategy to Combat Short SalesNASDAQ:NRXPNRX Pharmaceuticals Inc
03/11/20245:16PMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:NRXPNRX Pharmaceuticals Inc
03/11/20248:30AMPR Newswire (US)NRx Pharmaceuticals (NASDAQ:NRXP) Completes Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine)NASDAQ:NRXPNRX Pharmaceuticals Inc
03/06/20244:08PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRXPNRX Pharmaceuticals Inc
03/04/20248:30AMPR Newswire (US)NRx Pharmaceuticals (NASDAQ: NRXP) Announces Last Patient, Last Visit in its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar DepressionNASDAQ:NRXPNRX Pharmaceuticals Inc
03/01/20248:30AMPR Newswire (US)NRx Pharmaceuticals Announces Definitive Purchase Agreement for Common, Unregistered Shares at $0.38 per ShareNASDAQ:NRXPNRX Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:NRXP

Your Recent History

USOTC
KBLB
Kraig Biocraft Laborator... (QB)
USOTC
BIEL
Bioelectronics (PK)
USOTC
HIRU
Hiru (PK)
USOTC
SPZI
Spooz (PK)
USOTC
RONN
Ronn Motor (PK)
COIN
BTCUSD
Bitcoin
USOTC
VPLM
Voip Pal Com (QB)
NASDAQ
AVXL
Anavex Life Sciences
NASDAQ
COOP
Mr Cooper
USOTC
KEGS
1812 Brewing (PK)
NASDAQ
LWLG
Lightwave Logic
USOTC
DBMM
Digital Brand Media and ... (PK)
USOTC
NWBO
Northwest Biotherapeutics (QB)
NASDAQ
AMRN
Amarin
USOTC
IGPK
Intergrated Cannabis Sol... (PK)
USOTC
NSAV
Net Savings Link (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved